On April 15 the Food and Drug Administration (FDA) recently approved two drugs for the treatment of patients with advanced kidney cancer. Both approvals are for patients whose cancers have progressed after receiving prior treatment with drugs that block tumor blood vessel growth, known as antiangiogenic therapies.
The agency approved cabozantinib (Cabometyx™), and on May 13 it approved lenvatinib (Lenvima®) in combination with everolimus (Afinitor®). Read more here.
No comments:
Post a Comment